Abstract
Objectives Trauma screening is recommended for pregnant persons with opioid use disorder (OUD), but there is limited literature on screening results from buprenorphine treatment. This study's objectives were to 1) describe the types, and severity, of traumatic events reported and 2) evaluate the associations between trauma and health-related quality of life (HRQoL). Methods Baseline data from an ongoing trial were analyzed. Participants were 155 pregnant persons with OUD receiving, or enrolling in, buprenorphine treatment at one of 13 sites. The experience, and relative severity, of 14 high magnitude stressors were assessed with the trauma history screen. The Patient-Reported Outcomes Measurement Information System-29+2 was used to assess 8 HRQoL domains. Results Traumatic stressors were reported by 91% of the sample (n = 155), with 54.8% reporting a lifetime persisting posttraumatic distress (PPD) event and 29.7% reporting a childhood PPD event. The most prevalent lifetime PPD event was sudden death of a close family/friend (25.8%); physical abuse was the most prevalent childhood PPD event (10.3%). Participants with lifetime PPD, relative to no PPD, reported significantly greater pain interference (P = 0.02). Participants with childhood PPD, relative to no PPD, had significantly worse HRQoL overall (P = 0.01), and worse pain intensity (P = 0.002), anxiety (P = 0.003), depression (P = 0.007), fatigue (P = 0.002), and pain interference (P < 0.001). Conclusions A majority of pregnant persons enrolled/enrolling in buprenorphine treatment reported persisting posttraumatic distress with sudden death of close family/friend being the most prevalent originating event; clinicians should consider the impact that the opioid-overdose epidemic may be having in increasing trauma exposure in patients with OUD.
| Original language | English |
|---|---|
| Pages (from-to) | 20-25 |
| Number of pages | 6 |
| Journal | Journal of Addiction Medicine |
| Volume | 19 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2025 |
Bibliographical note
Publisher Copyright:© Wolters Kluwer Health, Inc. All rights reserved.
Funding
Sources of support: This work was supported by the National Institute of Health through the NIH HEAL Initiative under award numbers UG1DA013732 to the University of Cincinnati (T. John Winhusen), UG1DA049444 (Adam Gordon and Gerald Cochran), UG1DA015831 (Roger Weiss and Gail D\u2019Onofrio), UG1DA013727 (Kathleen Brady and Matthew Carpenter), UG1DA049468 (Kimberly Page), UG1DA015815 (Keith Humphreys and Todd Korthuis), UG1DA013720 (Jose Szapocznik, Daniel Feaster, and Lisa Metsch), UG1DA049436 (Jane Liebschutz and Judith Feinberg), and UG1DA013714 (John Roll and Mary Hatch-Maillette). The work was also supported by NIDA contracts to the CCC (HHSN271201500065C) and DSC (HHSN271201400028C). The Publications Committee of the National Drug Abuse Treatment Clinical Trials Network reviewed and gave approval for submission of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or its NIH HEAL Initiative. This work was supported by the National Institute of Health through the NIH HEAL Initiative under award numbers UG1DA013732 to the University of Cincinnati (T. John Winhusen), UG1DA049444 (Adam Gordon and Gerald Cochran), UG1DA015831 (Roger Weiss and Gail D'Onofrio), UG1DA013727 (Kathleen Brady and Matthew Carpenter), UG1DA049468 (Kimberly Page), UG1DA015815 (Keith Humphreys and Todd Korthuis), UG1DA013720 (Jose Szapocznik, Daniel Feaster, and Lisa Metsch), UG1DA049436 (Jane Liebschutz and Judith Feinberg), and UG1DA013714 (John Roll and Mary Hatch-Maillette). The work was also supported by NIDA contracts to the CCC (HHSN271201500065C) and DSC (HHSN271201400028C). The Publications Committee of the National Drug Abuse Treatment Clinical Trials Network reviewed and gave approval for submission of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or its NIH HEAL Initiative.
| Funders | Funder number |
|---|---|
| John Roll and Mary Hatch-Maillette | |
| Author National Institute on Drug Abuse DA031791 Mark J Ferris National Institute on Drug Abuse DA006634 Mark J Ferris National Institute on Alcohol Abuse and Alcoholism AA026117 Mark J Ferris National Institute on Alcohol Abuse and Alcoholism AA028162 Elizabeth G Pitts National Institute of General Medical Sciences GM102773 Elizabeth G Pitts Peter McManus Charitable Trust Mark J Ferris National Institute on Drug Abuse | |
| National Drug Abuse Treatment | |
| University of Cincinnati University Research Council | UG1DA013720, UG1DA049468, UG1DA015831, UG1DA049436, UG1DA049444, UG1DA013727, UG1DA013714, UG1DA015815 |
| University of Cincinnati University Research Council | |
| National Institutes of Health (NIH) | UG1DA013732 |
| National Institutes of Health (NIH) | |
| Direktion für Entwicklung und Zusammenarbeit | HHSN271201400028C |
| Direktion für Entwicklung und Zusammenarbeit | |
| Christian College Consortium | HHSN271201500065C |
| Christian College Consortium |
Keywords
- buprenorphine
- opioid use disorder
- pregnant
- quality of life
- trauma
ASJC Scopus subject areas
- Psychiatry and Mental health
- Pharmacology (medical)